FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to the treatment of primary nephrotic syndrome. The use of a compound of formula (II), including its stereoisomeric forms, or a pharmaceutically acceptable salt thereof for the treatment of primary nephrotic syndrome, as well as for the manufacture of a medicament for the treatment of primary nephrotic syndrome is disclosed.
EFFECT: use of the compound makes it possible to effectively treat primary nephrotic syndrome.
9 cl, 3 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ALPHA- AND GAMMA-MSH ANALOGUES | 2013 |
|
RU2668791C2 |
| PREVENTIVE OR THERAPEUTIC REMEDY FOR PHOTODERMATOSIS | 2021 |
|
RU2812785C1 |
| HUMAN ALDOSTERONE SYNTHASE (CYP11B2) INHIBITORS | 2022 |
|
RU2811745C1 |
| HUMAN ALDOSTERONE SYNTHASE (CYP11B2) INHIBITORS | 2023 |
|
RU2824362C1 |
| HUMAN CYTOCHROME 11B2 INHIBITORS | 2022 |
|
RU2800378C1 |
| COMBINATIONS WHICH INCLUDE RECEPTOR S1P AGONIST AND JAK3 KINASE INHIBITOR | 2005 |
|
RU2415678C2 |
| SUBSTITUTED DERIVATIVES OF BISPHENYL ESTER OF BUTYRIC ACID AS NEP INHIBITORS | 2019 |
|
RU2784522C2 |
| BICYCLIC HETEROCYCLIC COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | 2006 |
|
RU2426733C2 |
| 8-OXY-QUINOLINE DERIVATIVES AS BRADYKININ B2 RECEPTOR MODULATORS | 2008 |
|
RU2512541C2 |
| PYRAZOLOPYRIMIDONE OR PYRROLOTRIAZONE DERIVATIVES, METHOD OF PREPARING SAME AND PHARMACEUTICAL APPLICATIONS THEREOF | 2014 |
|
RU2674977C2 |
